Evidence map›Paper›PMID 34677796›Full record

ReviewNeuromolecular medicine2022

Emerging Epigenetic Therapies for Brain Tumors.

Lokesh Kukreja, Catherine J Li, Sathyapriya Ezhilan, Vishwanath R Iyer, John S Kuo

Abstract readReview
PubMed Publisher
In one paragraph

Review in Neuromolecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Lokesh KukrejaDepartment of Neurosurgery, Dell Medical School, The University of Texas at Austin, Austin, TX, USA.
Catherine J LiDepartment of Neurosurgery, Dell Medical School, The University of Texas at Austin, Austin, TX, USA.
Sathyapriya EzhilanDepartment of Neurosurgery, Dell Medical School, The University of Texas at Austin, Austin, TX, USA.
Vishwanath R IyerDepartment of Molecular Biosciences, LIVESTRONG Cancer Institutes and Department of Oncology, Dell Medical School, The University of Texas, Austin, TX, USA.
John S KuoDepartment of Neurosurgery, Mulva Clinic for the Neurosciences and LIVESTRONG Cancer Institutes and Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, TX, USA. john.kuo@austin.utexas.edu.ORCID 0000-0001-6809-4806
The University of Texas at Austin · USLivestrong Foundation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant brain tumors are among the most intractable cancers, including malignancies such as glioblastoma, diffuse midline glioma, medulloblastoma, and ependymoma. Unfortunately, treatment options for these brain tumors have been inadequate and complex, leading to poor prognoses and creating a need for new treatment modalities. Aberrant epigenetics define these types of tumors, with underlying changes in DNA methylation, histone modifications, chromatin structure and noncoding RNAs. Epigenetic-targeted therapies are an alternative that have the potential to reverse the epigenetic deregulation underpinning brain malignancies. Various drugs targeting epigenetic regulators have shown promise in preclinical and clinical testing. In this review, we highlight some of the recent emerging epigenetic targeted therapies for brain tumors being evaluated in the discovery phase and in clinical trials.

Indexed as

Brain NeoplasmsGliomaDNA MethylationEpigenesis, GeneticEpigenomicsHumansBrain tumorsClinical trialsEpigeneticMechanisms

Identifiers

PMID34677796
OpenAlexW3205253240

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.